Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

T cells expanded from PD-1+ peripheral blood lymphocytes share more clones with paired tumor-infiltrating lymphocytes

(2021) Tiepeng Li et al.   CANCER RESEARCH

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

(2021) Caicun Zhou et al.   CLINICAL CANCER RESEARCH

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

(2021) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial

(2021) Corinne Faivre-Finn et al.   Journal of Thoracic Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

(2021) Luis Paz-Ares et al.   LANCET ONCOLOGY

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

(2021) Jiajie Hou et al.   Nature Reviews Clinical Oncology

FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review

(2021) Paz J. Vellanki et al.   CLINICAL CANCER RESEARCH

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

(2021) Ahmet Sezer et al.   LANCET

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

(2021) Tina Cascone et al.   NATURE MEDICINE

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

(2021) Miguel F Sanmamed et al.   Cancer Discovery

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

(2021) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

(2021) Keunchil Park et al.   Journal of Thoracic Oncology

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

(2021) Tianqing Chu et al.   Journal of Thoracic Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

(2021) Nasser K Altorki et al.   LANCET ONCOLOGY

Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy—The Role of Liquid Biopsy in Unraveling the Puzzle

(2021) Elien Augustus et al.   Cancers

PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?

(2021) Alessandro Rizzo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

(2021) Sacha I. Rothschild et al.   JOURNAL OF CLINICAL ONCOLOGY

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

(2021) Mark A. Socinski et al.   Journal of Thoracic Oncology

Lung cancer

(2021) Alesha A Thai et al.   LANCET

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

(2021) Naoyuki Nogami et al.   Journal of Thoracic Oncology

A role for club cells in smoking-associated lung adenocarcinoma

(2021) Sabine J. Behrend et al.   European Respiratory Review

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

(2020) Matthew H. Taylor et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents

(2020) Paola Ciciola et al.   Journal of Clinical Medicine

Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma

(2020) Arnold Lee et al.   DRUGS

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement

(2020) Yuko Oya et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

(2020) Robert Jotte et al.   Journal of Thoracic Oncology

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations

(2020) Diego Kauffmann-Guerrero et al.   Oncology Research and Treatment

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer

(2020) Yinli Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Non–Small-Cell Lung Cancer in Never- and Ever-Smokers: Is It the Same Disease?

(2020) Andrew Tang et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

(2020) Yunpeng Yang et al.   Journal of Thoracic Oncology

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

(2020) Willemijn S M E Theelen et al.   Lancet Respiratory Medicine

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

(2020) Claire F Verschraegen et al.   Journal for ImmunoTherapy of Cancer

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma

(2020) Giuseppe Lamberti et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial

(2020) Makoto Nishio et al.   Journal of Thoracic Oncology

Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation

(2020) Jacob Sands et al.   Journal of Thoracic Oncology

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

(2020) Antonio Passaro et al.   Journal of Thoracic Oncology

Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions

(2020) Kathryn Banfill et al.   Journal of Thoracic Oncology

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

(2019) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

(2019) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

(2019) Neal Ready et al.   JOURNAL OF CLINICAL ONCOLOGY

Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib

(2019) A J Schoenfeld et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients

(2019) Michael J. Duffy et al.   CLINICAL CHEMISTRY

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer

(2019) Hongge Liang et al.   Cancer Management and Research

Th17/Treg cells imbalance and their related cytokines (IL-17, IL-10 and TGF-β) in children with autism spectrum disorder

(2019) Mai Moaaz et al.   JOURNAL OF NEUROIMMUNOLOGY

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

(2019) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer

(2019) Seongho Park et al.   Thoracic Cancer

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

(2018) Baohui Han et al.   BRITISH JOURNAL OF CANCER

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice

(2018) Passiglia Francesco et al.   Future Oncology

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes

(2018) Shisuo Du et al.   Journal of Thoracic Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

(2018) Kristina Buder-Bakhaya et al.   Frontiers in Immunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combinations of Bevacizumab With Cancer Immunotherapy

(2018) Daniel S. Chen et al.   CANCER JOURNAL

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

(2018) Karthik Suresh et al.   CHEST

Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors

(2018) Karthik Suresh et al.   Journal of Thoracic Oncology

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review

(2018) Bagher Farhood et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Is earlier better for melanoma checkpoint blockade?

(2018) Caroline Robert   NATURE MEDICINE

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States

(2018) Vamsidhar Velcheti et al.   PLoS One

PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

(2017) Tawee Tanvetyanon et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

(2017) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review

(2017) Robert Brody et al.   LUNG CANCER

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Radiotherapy and immunotherapy: a beneficial liaison?

(2017) Ralph R. Weichselbaum et al.   Nature Reviews Clinical Oncology

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

(2017) Priti S. Hegde et al.   SEMINARS IN CANCER BIOLOGY

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

(2017) Guillermo De Velasco et al.   Cancer Immunology Research

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Immunotherapy for lung cancer

(2016) Antonius Steven et al.   RESPIROLOGY

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

(2016) Giuseppe V. Masucci et al.   Journal for ImmunoTherapy of Cancer

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Nivolumab: A Review of Its Use in Patients with Malignant Melanoma

(2014) Emma D. Deeks   DRUGS

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) H. Wimberly et al.   Cancer Immunology Research

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens

(2014) Sofia R Gameiro et al.   OncoImmunology

Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

(2012) Hui Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY